Suboptimal Duration of Granulocyte Colony–stimulating Factor Use and Chemotherapy-induced Neutropenia in Women Diagnosed With Breast Cancer
Author:
Funder
National Science Council, Taiwan
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference33 articles.
1. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management;Crawford;Cancer,2004
2. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America;Freifeld;Clin Infect Dis,2011
3. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients;Kuderer;Cancer,2006
4. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP;Bosly;Ann Hematol,2008
5. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients;Chirivella;Breast Cancer Res Treat,2009
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prescription patterns of granulocyte colony–stimulating factors in patients with breast cancer: A real-world study;PLOS ONE;2023-07-17
2. Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis);BMC Cancer;2021-04-06
3. Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression;Breast Cancer: Targets and Therapy;2019-03
Nano-curcumin’s suppression of breast cancer cells (MCF7) through the inhibition of cyclinD1 expression
4. Cost‐effectiveness of granulocyte colony‐stimulating factor prophylaxis in chemotherapy‐induced febrile neutropenia among breast cancer and Non‐Hodgkin's lymphoma patients under Taiwan's national health insurance system;Journal of Evaluation in Clinical Practice;2016-08-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3